mRNA COVID-19 efficacy lower for immunocompromised adults
Nov 04, 2021
Vaccine effectiveness of two doses of mRNA vaccine lower against COVID-19-associated hospitalization, with variation by condition. mRNA vaccines approved to fight COVID-19 in the U.S. include Pfizer-BioNTech...
CDC: Vaccinated more likely to die during omicron wave if they got J&J shot
Mar 25, 2022
However, breakthrough infections among J&J vaccine recipients were similar or lower compared with the other vaccines.
‘Knowledge is power’ in campaign to improve staff vaccine uptake
By
Kimberly Bonvissuto
Apr 21, 2021
Knowledge is power. Forest Hills of DC, an assisted living, memory care, skilled nursing and short-term rehabilitation provider in the nation’s capital, used that mantra to move the needle on staff vaccine...
Prior SARS-CoV-2 infection ups protection for vaccinated
Nov 15, 2021
Prior infection was linked to a lower risk for breakthrough infection among individuals vaccinated with BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna).
FDA approves first RSV vaccine
May 03, 2023
Arexvy was ~82% effective in preventing RSV-induced lower respiratory tract infections in adults aged 60 or more years.
Age, cancer type affect COVID-19 vaccine uptake in cancer patients
Mar 16, 2023
Higher rates of vaccination were seen in older patients; lower rates were seen for metastatic solid tumors, with comorbidities.
Risk for breakthrough SARS-CoV-2 infection lower with mRNA-1273
Feb 02, 2022
The risk for breakthrough infection and of 60-day hospitalization was significantly lower for mRNA-1273 (Moderna) versus BNT162b2 (Pfizer-BioNTech) vaccination.
Omicron resists Pfizer vaccine but causes less severe disease
Dec 14, 2021
The risk for hospital admission among adults with COVID-19 was 29% lower than in the first pandemic wave, which began in March 2020.
Vaccine effectiveness up after three COVID-19 vaccine doses
Feb 14, 2022
Vaccine effectiveness was lower during the omicron- versus the delta-predominant period at all time points; it waned with increasing time since vaccination.
Effectiveness of mRNA COVID-19 vaccines lower at ≥120 days
Dec 09, 2021
Among U.S. veterans, vaccine effectiveness was 86%t for Moderna and 75% for Pfizer-BioNTech vaccines at ≥120 days after the second dose.